Prof. Xiaodong Zhu 朱小东
Chief Physician, Professor
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for tumors throughout the body, with a clinical and research focus on nasopharyngeal carcinoma and liver cancer.
Dr. Zhu is a Professor of Oncology and Chief Physician in Radiation Therapy at Guangxi Medical University Cancer Hospital. Dr. Zhu trained at the Cancer Hospital of the Chinese Academy of Medical Sciences and in Japan. Research focuses on nasopharyngeal and liver cancer radiation therapy. Dr. Zhu has led multiple national and provincial research projects and published over 160 papers.
Professional roles
- Vice Chair, Nasopharyngeal Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Tumor Radiotherapy Professional Committee, Wu Jieping Medical Foundation
- Standing Committee Member, Radiotherapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Radiation Oncology Professional Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Zhu Xiaodong). Papers usually list the name as Xiaodong Zhu or Zhu X.
Selected publications
119 papers on PubMed matched by name and affiliation; 88 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur J Radiol, 2026 (senior author): Development and validation of a multiparametric MRI habitat radiomics nomogram for predicting early complete response to induction chemoimmunotherapy in locally advanced nasopharyngeal carcinoma. PubMed 42541996
- Oral Oncol, 2026 (senior author): Pretreatment multiparametric MRI-based habitat radiomics and 2.5D deep learning for predicting early complete response to induction chemoimmunotherapy in locally advanced nasopharyngeal carcinoma. PubMed 42435493
- Int J Gen Med, 2026 (senior author): Prognostic Value of Platelet-Associated Biomarkers in Nasopharyngeal Carcinoma Patients Received IMRT: A Retrospective Study. PubMed 42578042
- Biol Direct, 2026 (senior author): Comprehensive multi-omics analysis reveals a fatty acid metabolism gene signature for prognostic assessment and immunotherapy in nasopharyngeal carcinoma, and identifies ABCC1 as a potential novel therapeutic target. PubMed 42351260
- Cancer Med, 2026 (senior author): The Prognostic Value of Serum Inflammatory Markers in Nasopharyngeal Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Multicenter Study. PubMed 42286988
- Transl Oncol, 2026 (senior author): Development and validation of prognostic nomograms based on peripheral blood T-cell counts and their dynamic changes for patients with nasopharyngeal carcinoma receiving radiotherapy. PubMed 41655557
- Transl Cancer Res, 2026 (senior author): Multi-parameter magnetic resonance imaging (MRI) deep learning radiomics predicts complete response after induction immunochemotherapy in locally advanced nasopharyngeal carcinoma. PubMed 41815125
- Clin Exp Med, 2025 (senior author): Integrated machine learning and single-cell analysis identify chromatin-remodeling gene signature for diagnosis and prognosis in nasopharyngeal carcinoma. PubMed 41249704
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion